Dimethyl fumarate treatment of relapsing-remitting multiple sclerosis influences B-cell subsets

Neurology: Neuroimmunology and NeuroInflammation

Volumn 3, Issue 2, 2016, Pages

  Lundy, Steven K ^a   Wu, Qi ^a   Wang, Qin ^a   Dowling, Catherine A ^a   Taitano, Sophina H ^a   Mao, Guangmei ^a   Mao Draayer, Yang ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADP RIBOSYL CYCLASE/CYCLIC ADP RIBOSE HYDROLASE 1; CD24 ANTIGEN; CD27 ANTIGEN; CD40 LIGAND; FUMARIC ACID DIMETHYL ESTER; INTERLEUKIN 10; LEUKOSIALIN;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE SUBPOPULATION; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HUMAN; HUMAN CELL; MALE; MEMORY CELL; MIDDLE AGED; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELAPSE;

EID: 85033465141     PISSN: None     EISSN: 23327812     Source Type: Journal    
DOI: 10.1212/NXI.0000000000000211     Document Type: Article

References (39)

1. Kim W, Zandona ME, Kim SH, Kim HJ. Oral diseasemodifying therapies for multiple sclerosis. J Clin Neurol 2015;11:9-19.
2. Cross AH, Naismith RT. Established and novel diseasemodifying treatments in multiple sclerosis. J Intern Med 2014;275:350-363.
3. Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-1107.
4. Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-1097.
5. Sheremata W, Brown AD, Rammohan KW. Dimethyl fumarate for treating relapsing multiple sclerosis. Expert Opin Drug Saf 2015;14:161-170.
6. Dubey D, Kieseier BC, Hartung HP, et al. Dimethyl fumarate in relapsing-remitting multiple sclerosis: rationale, mechanisms of action, pharmacokinetics, efficacy and safety. Expert Rev Neurother 2015;15:339-346.
7. Wang Q, Chuikov S, Taitano S, et al. Dimethyl fumarate protects neural stem/progenitor cells and neurons from oxidative damage through Nrf2-ERK1/2 MAPK pathway. Int J Mol Sci 2015;16:13885-13907.
8. Rosenkranz T, Novas M, Terborg C. PML in a patient with lymphocytopenia treated with dimethyl fumarate. N Engl J Med 2015;372:1476-1478.
9. Nieuwkamp DJ, Murk JL, van Oosten BW, et al. PML in a patient without severe lymphocytopenia receiving dimethyl fumarate. N Engl J Med 2015;372:1474-1476.
10. Bartsch T, Rempe T, Wrede A, et al. Progressive neurologic dysfunction in a psoriasis patient treated with dimethyl fumarate. Ann Neurol 2015;78:501-514.
11. Spencer CM, Crabtree-Hartman EC, Lehmann-Horn K, Cree BA, Zamvil SS. Reduction of CD8(1) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate. Neurol Neuroimmunol Neuroinflamm 2015; 2:e76. doi: 10.1212/NXI.0000000000000076.
12. Berkovich R, Weiner LP. Effects of dimethyl fumarate on lymphocyte subsets. Mult Scler Relat Disord 2015;4: 339-341.
13. Ockenfels HM, Schultewolter T, Ockenfels G, Funk R, Goos M. The antipsoriatic agent dimethylfumarate immunomodulates T-cell cytokine secretion and inhibits cytokines of the psoriatic cytokine network. Br J Dermatol 1998;139:390-395.
14. Schilling S, Goelz S, Linker R, Luehder F, Gold R. Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration. Clin Exp Immunol 2006;145:101-107.
15. Treumer F, Zhu K, Glaser R, Mrowietz U. Dimethylfumarate is a potent inducer of apoptosis in human T cells. J Invest Dermatol 2003;121:1383-1388.
16. Mann MK, Maresz K, Shriver LP, Tan Y, Dittel BN. B cell regulation of CD41CD251 T regulatory cells and IL-10 via B7 is essential for recovery from experimental autoimmune encephalomyelitis. J Immunol 2007;178: 3447-3456.
17. Matsushita T, Horikawa M, Iwata Y, Tedder TF. Regulatory B cells (B10 cells) and regulatory T cells have independent roles in controlling experimental autoimmune encephalomyelitis initiation and late-phase immunopathogenesis. J Immunol 2010;185:2240-2252.
18. Schimrigk S, Brune N, Hellwig K, et al. Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study. Eur J Neurol 2006;13:604-610.
19. Sanz I, Wei C, Lee FE, Anolik J. Phenotypic and functional heterogeneity of human memory B cells. Semin Immunol 2008;20:67-82.
20. Blair PA, Chavez-Rueda KA, Evans JG, et al. Selective targeting of B cells with agonistic anti-CD40 is an efficacious strategy for the generation of induced regulatory T2-like B cells and for the suppression of lupus in MRL/lpr mice. J Immunol 2009;182:3492-3502.
21. Blair PA, Norena LY, Flores-Borja F, et al. CD19(+) CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. Immunity 2010;32: 129-140.
22. Griffin DO, Holodick NE, Rothstein TL. Human B1 cells in umbilical cord and adult peripheral blood express the novel phenotype CD20+ CD27+ CD43+ CD70. J Exp Med 2011;208:67-80.
23. Iwata Y, Matsushita T, Horikawa M, et al. Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood 2011;117: 530-541.
24. Tsubaki M, Ogawa N, Takeda T, et al. Dimethyl fumarate induces apoptosis of hematopoietic tumor cells via inhibition of NF-kappaB nuclear translocation and downregulation of Bcl-xL and XIAP. Biomed Pharmacother 2014;68:999-1005.
25. Moed H, Stoof TJ, Boorsma DM, et al. Identification of anti-inflammatory drugs according to their capacity to suppress type-1 and type-2 T cell profiles. Clin Exp Allergy 2004;34:1868-1875.
26. de Jong R, Bezemer AC, Zomerdijk TP, van de Pouw-Kraan T, Ottenhoff TH, Nibbering PH. Selective stimulation of T helper 2 cytokine responses by the antipsoriasis agent monomethylfumarate. Eur J Immunol 1996;26:2067-2074.
27. Klinker MW, Reed TJ, Fox DA, Lundy SK. Interleukin-5 supports the expansion of fas ligand-expressing killer B cells that induce antigen-specific apoptosis of CD4(+) T cells and secrete interleukin-10. PLoS One 2013;8: e70131.
28. Scannevin RH, Chollate S, Jung MY, et al. Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroidderived 2)-like 2 pathway. J Pharmacol Exp Ther 2012; 341:274-284.
29. Sun L, Shi T, Qiao H, et al. Hepatic overexpression of heme oxygenase-1 improves liver allograft survival by expanding T regulatory cells. J Surg Res 2011;166:e187-194.
30. George JF, Braun A, Brusko TM, et al. Suppression by CD4+CD25+ regulatory T cells is dependent on expression of heme oxygenase-1 in antigen-presenting cells. Am J Pathol 2008;173:154-160.
31. Lin SX, Lisi L, Dello Russo C, et al. The antiinflammatory effects of dimethyl fumarate in astrocytes involve glutathione and heme oxygenase-1. ASN Neuro 2011;3:e00055.
32. Griffin DO, Rothstein TL. Human "orchestrator" CD11b (+) B1 cells spontaneously secrete interleukin-10 and regulate T-cell activity. Mol Med 2012;18:1003-1008.
33. Schubert RD, Hu Y, Kumar G, et al. IFN-beta treatment requires B cells for efficacy in neuroautoimmunity. J Immunol 2015;194:2110-2116.
34. Grutzke B, Hucke S, Gross CC, et al. Fingolimod treatment promotes regulatory phenotype and function of B cells. Ann Clin Transl Neurol 2015;2:119-130.
35. Rovituso D, Heller S, Schroeter M, Kleinschnitz C, Kuerten S. B1 cells are unaffected by immune modulatory treatment in remitting-relapsing multiple sclerosis patients. J Neuroimmunol 2014;272:86-90.
36. Begum-Haque S, Christy M, Ochoa-Reparaz J, et al. Augmentation of regulatory B cell activity in experimental allergic encephalomyelitis by glatiramer acetate. J Neuroimmunol 2011;232:136-144.
37. Begum-Haque S, Sharma A, Christy M, et al. Increased expression of B cell-associated regulatory cytokines by glatiramer acetate in mice with experimental autoimmune encephalomyelitis. J Neuroimmunol 2010;219:47-53.
38. Villar LM, Espino M, Roldan E, et al. Increased peripheral blood CD5+ B cells predict earlier conversion to MS in high-risk clinically isolated syndromes. Mult Scler 2011; 17:690-694.
39. Seidi OA, Semra YK, Sharief MK. Expression of CD5 on B lymphocytes correlates with disease activity in patients with multiple sclerosis. J Neuroimmunol 2002;133:205-210.